ERBB2 and breast carcinoma: Localization of lesions could be further enhanced by conjugation of MNPs with Herceptin directed specifically against the genetic profile of breast cancers that are Her2 positive such as in numerous previous studies using Herceptin conjugated MNPs to localize breast lesions in vitro and in vivo [9–14].